ABCLAbCellera Biologics
+5.2% today · +219.7% over a year
1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 14% of the instruments we score
Trend: among the best of its peers; Quality, Stability: among the weakest; priced higher than most peers. No dividend.
AbCellera Biologics (ABCL) valuation against sector peers: P/B 3.8, free-cash-flow yield −0.8%, P/S 60.2.
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | ABCL | Sector median | vs median |
|---|---|---|---|
| P/E | — | 25.8 · n=26 | — |
| P/B | 3.8 | 3.6 · n=45 | 6% above |
| P/S | 60.2 | 4.7 · n=40 | 1,180% above |
| EV/EBIT | — | 22.8 · n=28 | — |
| Free-cash-flow yield | −0.8% | 3.8% · n=39 | 121% below |
| Dividend yield | 0.00% | 0.19% · n=99 | 100% below |
| Return on equity | −14.6% | 5.2% · n=56 | 381% below |
| Return on invested capital | −22.7% | 6.5% · n=47 | 451% below |
| Gross margin | — | 70.2% · n=39 | — |
| Net debt / EBITDA | — | 2.08 · n=25 | — |
Value factor: 12 of 100 within the peer group. Full score breakdown →
Sector peers
The largest companies of the same sector and region.
| NVSNovartis AG | 22.3 | 6.8 | 18.7 | 5.6% | 2.4% | 10/10 |
|---|---|---|---|---|---|---|
| NOVNNovartis AG | 22.2 | 6.7 | 18.6 | 5.7% | 2.8% | 10/10 |
| AZNAstraZeneca PLC | 28.7 | 6.0 | 23.1 | 4.0% | 1.1% | 5/10 |
| AZNAstraZeneca plc | 28.6 | 6.0 | 23.0 | 4.0% | 1.7% | 6/10 |
| NVONovo Nordisk A/S | 12.0 | 6.3 | 10.4 | 4.8% | 4.5% | 8/10 |
| SNYSanofi | 13.4 | 1.5 | 18.2 | 6.9% | 4.4% | 7/10 |
| SANSanofi SA | 13.4 | 1.5 | 18.2 | 6.9% | 4.8% | 9/10 |
| GSKGSK plc | 14.4 | 5.0 | 11.7 | 7.8% | 3.6% | 9/10 |
| TEVATeva Pharmaceutical Industries Limited | 99.1 | 6.3 | 43.8 | 2.5% | 0.0% | 6/10 |
| ALCAlcon | 37.4 | 1.7 | 29.2 | 4.7% | 0.4% | 4/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 09 Nov 2026
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.